p38 MAP kinase is activated at early stages in Alzheimer's disease brain

Anyang Sun, Mei Liu, Xuan V. Nguyen, Guoying Bing

Research output: Contribution to journalArticlepeer-review

157 Scopus citations

Abstract

The regional, cellular, and subcellular localization of phosphorylated p38 MAPK (pp38) was examined by immunocytochemistry, immuofluorescent multiple labeling, and immunoblotting of extracts as well as immunoprecipitates of human postmortem tissue from control and Alzheimer's disease (AD) cases at different Braak stages. "Early AD" cases (Braak stages IV-V) and a subset of Braak stage VI cases have high levels of pp38 immunoreactivity, with the most dense immunoreactivity located in CA2 and subiculum followed by CA1 in the hippocampus. On the contrary, very little pp38 was detected in age-matched controls (Braak stages 0-II). More importantly, as revealed by various multiple labeling experiments, pp38 immunoreactivity is mainly located in neurons bearing early neurofibrillary pathology, but not in typically fibrillar tangles that are densely stained by thioflavin-S. Most pp38-positive neurons only contain a small amount of phospho-tau. Additionally, pp38 immunoreactivity was not associated with senile plaques. At the subcellular level, pp38-immunoreactive granules are usually larger than the granules stained with the lysosomal marker cathepsin D. Immunoblotting with different extraction buffers and immunoprecipitation indicate that pp38 does not or only loosely binds to phospho-tau. Taken together, this study demonstrates that p38 MAPK is activated at early stages of neurofibrillary degeneration in AD hippocampus. The p38 activation may also be linked to neurodegeneration through mechanisms other than neurofibrillary tangle formation.

Original languageEnglish
Pages (from-to)394-405
Number of pages12
JournalExperimental Neurology
Volume183
Issue number2
DOIs
StatePublished - Oct 1 2003

Bibliographical note

Funding Information:
Human brain sections used in this study were kindly provided by the University of Kentucky Alzheimer’s Disease Research Center headed by Dr. William R. Markesbery. Ann Tudor cut the sections for this study. The authors gratefully acknowledge Dr. Peter Davies for providing TG3 and PHF-1 antibodies and Dr. Peter Seubert for providing 12E8 antibody. This work was supported by NIH Grant 3R01 NS39345-01 (G.B.).

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Fingerprint

Dive into the research topics of 'p38 MAP kinase is activated at early stages in Alzheimer's disease brain'. Together they form a unique fingerprint.

Cite this